Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin

Lung Cancer

Volumn 45, Issue 2, 2004, Pages 227-236

  Buccheri, Gianfranco ^a   Ferrigno, Domenico ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Non small cell lung cancer; Paclitaxel; Phase II study; Second line treatment

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE SODIUM PHOSPHATE; LAXATIVE; METOCLOPRAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PHENIRAMINE MALEATE; PLATINUM; RANITIDINE; VINBLASTINE;

ADULT; AGED; ALOPECIA; ANAMNESIS; ANEMIA; ARTICLE; ASTHMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL TYPE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FLUID RETENTION; GRANULOCYTOPENIA; HUMAN; INFECTION; INFORMED CONSENT; INJECTION PAIN; INJECTION SITE; LABORATORY TEST; LEUKOCYTE; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MENTAL INSTABILITY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; PATIENT ATTITUDE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; REFRACTORY PERIOD; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTE; TOXICITY; TREATMENT FAILURE; TUMOR REGRESSION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; PROBABILITY; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TERMINALLY ILL;

EID: 3042752142     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.01.011     Document Type: Article

References (30)

1. Greenlee R.T., Hill-Harmon M.B., Murray T. Cancer statistics, 2001. CA Cancer J. Clin. 51:2001;15-37
2. American Thoracic Society, European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med 1998;15:320-32.
3. Buccheri G. Chemotherapy and survival in non-small cell lung cancer. The old 'vexata questio'. Chest. 99:1991;1328-1329
4. Buccheri G. Chemotherapy and survival in non-small cell lung cancer: three years later. Chest. 10:1994;990-992
5. Alberti W., Anderson G., Bartolucci A., Bell D., Villalba J.B., Brodin O., et al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 31:1995;899-909
6. American Society of Clinical Oncology. Clinical practice guidelines for treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1998;15:2996-3018.
7. Ferrigno D., Buccheri G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer. 29:2000;91-104
8. Huisman C., Smit E.F., Giaccone G., Postmus P.E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J. Clin. Oncol. 18:2000;3722-3730
9. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2000;2095-2103
10. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandier A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 34:2002;92-98
11. Koumakis G., Demiri M., Barbounis V., Vassilomanolakis M., Gontikakis E., Pamouksoglou P., et al. Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial. Lung Cancer. 35:2002;315-317
12. World Health Organization. International histological classification of tumours. Berlin: Springer-Verlag; 1991.
13. Zubrod C.G., Scheiderman M.A., Frei E., Brindley C., Gold L.G., Shnider B., et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J. Chron. Dis. 11:1960;7-33
14. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214
15. Buccheri G.F., Ferrigno D., Curcio A., Vola F., Rosso A. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer. 63:1989;428-432
16. Buccheri G. Tumor markers: clinical meaning and use. In: Brambilla C, Brambilla E, editors. Lung tumors. New York: Marcel Dekker; 1999. p. 435-52.
17. Buccheri G., Ferrigno D. Cytokeratin-derived markers of lung cancer. Expert Rev. Mol. Diagn. 1:2001;315-322
18. Mountain C.F. Revisions in the international system for staging lung cancer (see comments). Chest. 11:1997;1710-1717
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials. 10:1989;1-10
20. Kaplan E.L., Meier F. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 58:1958;457-481
21. Le Chevalier T., Brisgand D., Douillard J.-Y., Pujol J.-L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Oncol. 12:1994;360-367
22. Buccheri G., Ferrigno D. Randomized trial of platin (MVP) vs. non-platin-chemotherapy (MACC) in non-small cell lung cancer: a negative report from the Cuneo Lung Cancer Study Group (CuLCaSG). Lung Cancer. 18(Suppl 1):1997;7
23. National Cancer Institute. PDQ Treatment Health Professionals. Non-small cell lung cancer; 2002 [http://cancernet.nci.nih.gov/clinpdq/soa/Non- small_cell_lung_cancer_Phisician.htlm].
24. Socinski M.A. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist. 4:1999;408-416
25. Ranson M., Davidson N., Nicolson M., Falk S., Carmichael J., Lopez P., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 92:2000;1074-1080
26. Alberola V., Cortesi E., Juan O. Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 44(Suppl):2002;31-41
27. Juan O., Albert A., Ordono F., Casany R., Caranana V., Campos J.M., et al. Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study. Jpn. J. Clin. Oncol. 32:2002;449-454
28. Socinski M.A., Schell M.J., Bakri K., Peterman A., Lee J.H., Unger P., et al. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer. 95:2002;1265-1273
29. Sculier J.P., Berghmans T., Lafitte J.J., Richez M., Recloux P., Van Cutsem O., et al. A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung Cancer. 37:2002;73-77
30. Buccheri G., Ferrigno D., Rosso A., Vola F. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer. 6:1990;87-98